AstraZeneca's Mixed Lung Trials
AstraZeneca Halts Lung Cancer Trial While Reporting Positive Results for Another Treatment
Key Points
The eVOLVE-Lung02 trial of volrustomig plus chemotherapy targeted a PD-L1–negative NSCLC subset, specifically patients with tumors expressing PD-L1 below 50%.
The eVOLVE-Lung02 trial enrolled 895 participants across 25 countries, illustrating the global scale of this investigation.
The SAFFRON trial results were reported in partnership with HUTCHMED, showing that Tagrisso (osimertinib) plus Orpathys (savolitinib) significantly improved progression-free and overall survival versus standard chemotherapy.
Following the updates, AstraZeneca’s shares traded lower, around a 2% drop, reflecting market reaction to the mixed news on the lung-cancer program.
AstraZeneca has shut down its eVOLVE-Lung02 Phase III trial of volrustomig combined with chemotherapy for metastatic non-small-cell lung cancer (mNSCLC). Nasdaq reported that an independent data monitoring committee found the trial was unlikely to hit its primary goals, prompting the company to pull the plug.
The news sent AstraZeneca shares down roughly 2%, according to Yahoo Finance. But the company also released positive data from a separate lung cancer trial, painting a mixed picture for its oncology pipeline.
Why the eVOLVE-Lung02 Trial Was Stopped
The eVOLVE-Lung02 trial targeted a specific group of NSCLC patients — those whose tumors express PD-L1 below 50%. PD-L1 is a protein that helps cancer cells hide from the immune system. Patients with low PD-L1 levels are harder to treat with standard immunotherapy. The trial enrolled 895 participants across 25 countries, making it a large, global effort.
Despite the scale, the independent data monitoring committee reviewed the results and concluded the trial could not reach its targets. MarketScreener noted that AstraZeneca said there were no new safety signals. The company said the safety profile matched what was already known about the drug.
Tagrisso Plus Orpathys Delivers a Bright Spot
On the same day, AstraZeneca reported good news from the SAFFRON trial. That study, run with partner HUTCHMED, tested Tagrisso (osimertinib) combined with Orpathys (savolitinib). The combination significantly improved both progression-free survival and overall survival compared to standard chemotherapy, according to Yahoo Finance.
Progression-free survival measures how long a patient lives without their cancer getting worse. Overall survival measures how long they live, period. Beating standard chemotherapy on both counts is a strong result. The SAFFRON data gives AstraZeneca a meaningful win to point to even as the volrustomig setback grabs headlines.
Volrustomig Still Has a Fighting Chance Elsewhere
AstraZeneca is not giving up on volrustomig entirely. MarketScreener reported that the company plans to keep running late-stage trials of the drug in three other cancer types: cervical cancer, head and neck squamous cell carcinoma, and mesothelioma. These trials remain active.
The company also said it will work with investigators to make sure patients already enrolled in the stopped trial continue to receive care. Volrustomig is part of AstraZeneca's broader push into immuno-oncology — treatments that use the immune system to fight cancer. The lung trial failure is a blow, but the drug still has multiple shots at proving its value.
Mixed Results Leave AstraZeneca's Lung Portfolio at a Crossroads
The back-to-back announcements highlight the uneven state of AstraZeneca's lung cancer program. One major trial failed. Another posted strong survival data. Shares fell about 2% on the day, suggesting investors focused more on the miss than the win, according to Yahoo Finance.
AstraZeneca is betting on a diversified strategy — no single drug or combination carries the whole program. The SAFFRON results keep Tagrisso near the center of that strategy. Meanwhile, the company will look to data from its remaining volrustomig trials to decide its next move. Investors and oncologists alike will be watching closely.
Sentiment
Mostly NegativePublishers
15
Articles
95
Reach
110
